Migraine

This week on MDNN: Autism Spectrum Disorder rates are rising in the US, handwashing is effective for C. diff prevention, and PROMISE 1 trial results have been reported.

A massive genetic family migraine patient study found more defined risk scores for migraine subtypes.

Patients who had previously failed ≥2 preventative migraine treatments were effectively treated with galcanezumab, especially when compared to placebo.

Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.

Trial results on the recently FDA-approved gammaCore device will be presented at the American Academy of Neurology (AAN) annual meeting.

Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.

Migraine was associated with a higher incidence of myocardial infarction, and ischaemic and haemorrhagic stroke.

The 50-mg dose showed that 19.2% of patients were free of pain after 2 hours while the 100-mg dose resulted in 21.2% of pain-free patients.

Migraine patients have been found to suffer more than nearly all other chronic pain patients but can be relieved by surgery.

The Alder Pharmaceuticals product showed an average reduction of 8.2 monthly headache days.

Over a 12-month period, the drug showed a statistically significant reduction in the number of monthly migraine headache days.

Eli Lilly drug reduces migraines by 4 to 5 days per month.

Peter Goadsby, M.B., B.S., Director of the NIHR- Wellcome Trust King’s Clinical Research, London, Professor of Neurology, University of California at San Francisco, explained the benefits of the recent FDA approval of the gammaCore non-invasive vagal nerve stimulator on patients suffering from cluster headaches.

Previous studies link vagus nerve stimulation to pain relief for various conditions.

Study results on the link between vitamin D and headache have a history of being ambiguous, but new research found more conclusive findings.

For individuals battling migraines, a morning cup of coffee or extra glass of wine can act as devastating headache triggers. Rather than excess caffeine, the true migraine trigger culprits are nitrites and monosodium glutamate (MSG).

Do you suffer from migraines? Cluster headaches? Tension headaches? Other kinds of headaches? All of them are related to a thyroid disorder, according to new research from the University of Cincinnati (UC).

Despite the availability of several treatment options, many people with migraine aren’t satisfied with their outcomes, according to the national Migraine in America 2016 survey created by Health Union.

People with traumatic brain injury (TBI) often times suffer from serious headaches. But if the patient wants to take potentially addictive opioids off the table, what’s another option?